Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Dynavax Technologies (NASDAQ:DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Participants are advised to join approximately 10 minutes before the call starts. The webcast will be accessible through the company's investor relations website, with a replay available for 30 days.
Dynavax currently markets two commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant, which is used in multiple COVID-19 vaccines.
Dynavax Technologies (NASDAQ:DVAX), un'azienda biofarmaceutica in fase commerciale specializzata nello sviluppo di vaccini innovativi, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025, dopo la chiusura del mercato statunitense.
La società terrà una conference call e una trasmissione audio in webcast alle 16:30 ET/13:30 PT dello stesso giorno. Si consiglia ai partecipanti di collegarsi circa 10 minuti prima dell'inizio della chiamata. Il webcast sarà accessibile tramite il sito web delle relazioni con gli investitori della società, con una registrazione disponibile per 30 giorni.
Dynavax commercializza attualmente due prodotti: il vaccino HEPLISAV-B per la prevenzione dell'epatite B e l'adiuvante CpG 1018, utilizzato in diversi vaccini contro il COVID-19.
Dynavax Technologies (NASDAQ:DVAX), una empresa biofarmacéutica en etapa comercial enfocada en el desarrollo innovador de vacunas, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025, después del cierre del mercado estadounidense.
La compañía realizará una llamada de conferencia y una transmisión en audio webcast a las 4:30 p.m. ET/1:30 p.m. PT ese mismo día. Se recomienda a los participantes conectarse aproximadamente 10 minutos antes de que comience la llamada. El webcast estará disponible a través del sitio web de relaciones con inversionistas de la compañía, con una repetición accesible durante 30 días.
Dynavax comercializa actualmente dos productos: la vacuna HEPLISAV-B para la prevención de la hepatitis B y el adyuvante CpG 1018, que se utiliza en varias vacunas contra el COVID-19.
Dynavax Technologies (NASDAQ:DVAX)는 혁신적인 백신 개발에 주력하는 상업 단계의 바이오제약 회사로, 2025년 8월 7일 목요일, 미국 시장 마감 후에 2025년 2분기 재무 실적 발표를 예정하고 있습니다.
회사는 같은 날 오후 4시 30분 ET / 오후 1시 30분 PT에 컨퍼런스 콜 및 오디오 웹캐스트를 진행할 예정입니다. 참가자들은 통화 시작 약 10분 전에 접속할 것을 권장합니다. 웹캐스트는 회사 투자자 관계 웹사이트를 통해 접속 가능하며, 30일간 다시보기 서비스가 제공됩니다.
Dynavax는 현재 두 가지 상업용 제품을 판매하고 있습니다: B형 간염 예방을 위한 HEPLISAV-B 백신과 여러 COVID-19 백신에 사용되는 CpG 1018 보조제입니다.
Dynavax Technologies (NASDAQ:DVAX), une société biopharmaceutique en phase commerciale spécialisée dans le développement de vaccins innovants, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le jeudi 7 août 2025, après la clôture du marché américain.
La société organisera une conférence téléphonique et une diffusion audio en webcast à 16h30 ET / 13h30 PT le même jour. Il est conseillé aux participants de se connecter environ 10 minutes avant le début de l'appel. Le webcast sera accessible via le site web des relations investisseurs de la société, avec une rediffusion disponible pendant 30 jours.
Dynavax commercialise actuellement deux produits : le vaccin HEPLISAV-B pour la prévention de l'hépatite B et l'adjuvant CpG 1018, utilisé dans plusieurs vaccins contre la COVID-19.
Dynavax Technologies (NASDAQ:DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf innovative Impfstoffentwicklung, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025 nach Börsenschluss in den USA geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT eine Telefonkonferenz und eine Audio-Webcast veranstalten. Teilnehmer werden gebeten, sich etwa 10 Minuten vor Beginn der Konferenz einzuwählen. Der Webcast ist über die Investor-Relations-Website des Unternehmens zugänglich und steht für 30 Tage als Aufzeichnung zur Verfügung.
Dynavax vertreibt derzeit zwei kommerzielle Produkte: den HEPLISAV-B Impfstoff zur Hepatitis-B-Prävention und den CpG 1018 Adjuvans, der in mehreren COVID-19-Impfstoffen verwendet wird.
- None.
- None.
Dynavax will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-august-7-2025-302516281.html
SOURCE Dynavax Technologies
FAQ
When will Dynavax (DVAX) report Q2 2025 earnings?
What time is the Dynavax (DVAX) Q2 2025 earnings call?
How can I access Dynavax's (DVAX) Q2 2025 earnings webcast?
What are Dynavax's (DVAX) main commercial products?
